Iktos
iktos.ai
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Iktos combines generative AI, retrosynthesis and robotics to accelerate small-molecule drug discovery from design to preclinical candidate, reducing timelines to under 24 months.
News
Now Iktos teams up with Pierre Fabre in oncology
As Servier announces its partnership with Paris, France-based Iktos, now Pierre Fabre Laboratories has revealed an integrated collaboration with Iktos
Read more
Report
Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design
Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a research collaboration with Zealand Pharma A/S, a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and pred
Read more
Report
Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design
Read more
Report
Iktos and Astrogen Announce a Research Collaboration to Use Artificial Intelligence Platform for Drug Design against a Novel Parkinson's Disease Target
Read more
Report
Iktos and The University of Dundee, Drug Discovery Unit (DDU) Announce a Collaboration to Use AI for Drug Design and Retrosyntheis
Iktos, a company specialized in Artificial Intelligence for new drug design, and The Drug Discovery Unit (DDU), School of Life Sciences, The University of Dundee, focused on the discovery of therapeutics
Read more
Report
Pro access
Upgrade to see all 7 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.